13e18e29-9f8a-4bd4-9a5d-e6c30668d07a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- COAGULATION+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- MYOGENESIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- UV_RESPONSE_UP+0.200
- XENOBIOTIC_METABOLISM+0.200
- APICAL_JUNCTION+0.100
- DNA_REPAIR+0.100
Top 10 suppressed
- UV_RESPONSE_DN-0.500
- ANDROGEN_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MYC_TARGETS_V1-0.400
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.844 |
| 2 | SRR1318372 | GTEX | — | 0.842 |
| 3 | c2e34dda-0852-492e-9cde-3ff606259c12 | — | — | 0.834 |
| 4 | 4f521ce8-4aac-4ea5-abbe-732ff9ac5409 | — | — | 0.834 |
| 5 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.829 |
| 6 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.827 |
| 7 | SRR25043618 | — | — | 0.825 |
| 8 | SRR1316535 | GTEX | — | 0.825 |
| 9 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.819 |
| 10 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |